The majority of metastatic colorectal cancer patients who bear MMR proficient tumors or tumors with KRAS mutations (besides KRAS G12C) have few options available besides chemotherapy and anti-angiogenic agents [8]. The gene discussed is KRAS; the disease is metastatic colorectal cancer.